Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission

Background & Aims Little is known about the relationship between ustekinumab exposure during first 2 weeks of treatment and outcomes patients with Crohn’s disease (CD). We investigated serum concentrations endoscopic biochemical remission in CD. Methods In a prospective observational study, we measured samples from 41 consecutive who started (approximately 6 mg/kg, intravenously, then 90 mg every 8 weeks), due to markers active CD, at single center October 2017 through January 2019. parameters (peak concentration immediately after intravenous infusion, week concentration, area under curve 2). correlation these (simple score for CD scores 3 or less without ulceration, assessed centrally) (level fecal calprotectin below 100 mg/kg) using Mann-Whitney U test. Results Endoscopic was achieved 10 (24.4%) 24; 17 (41.5%) 8, 16, 21 (51.2%) 24. Peak associated (area receiver operating characteristic curve, 0.717; 95% CI, 0.517–0.916); 13 (46%) peak above 105 ?g/mL (upper tercile) remission, compared only 1 14 (7%) 88 (lower tercile). All were remission. There no significant difference associations concentrations, week-2 2, later measures (at 4 8) Conclusions found that as early hour infusion might be used identify most likely achieve This measurement optimize